Key result
Pioglitazone treatment was associated with the lowest HbA1c and blood pressure and the highest NOx levels, whereas SGLT2 inhibitors had the lowest impact on these endothelial biomarkers.
Why the study?
Diabetic vascular complications contribute to morbidity and mortality, with endothelial dysfunction consistently observed in diabetes, prompting investigation into how various treatment modalities affect endothelial biomarkers in T2DM.
Do different antidiabetic medications differentially impact endothelial dysfunction biomarkers in patients with T2DM?
Observational (n=182)
Do different antidiabetic medications differentially impact endothelial dysfunction biomarkers in patients with T2DM?
Pioglitazone may offer superior protection against endothelial dysfunction in T2DM compared to other antidiabetic agents like SGLT2 inhibitors, as evidenced by favorable biomarker profiles.
Pioglitazone was associated with favorable endothelial biomarkers in T2DM; leaves open comparative efficacy versus SGLT2i in prospective trials.
Major contributors to morbidity and mortality in diabetic patients are diabetic vascular complications.The impairment of endothelial function seems to be a constant observation in people with diabetes.The objective of the current study was to investigate the impact of various treatment modalities on the endothelial biomarker in T2DM.This study involved 182 participants, divided into seven groups: 20 healthy subjects as a control, 35 newly diagnosed patients with diabetes without treatment, and 127 patients already on different antidiabetic medications for three months.Levels of cholesterol, triglycerides (TG), low-density lipoprotein (LDL), glycated hemoglobin (HbA1c), random blood sugar (RBS), oxidized nitric oxide (NOx), endoglin (ENG), intercellular adhesion molecule (ICAM-1), and glutathione (GSH) are measured for all participants compared with the healthy control.All the other groups significantly increased their lipid profile, HbA1c, RBS, and blood pressure, with a high significance observed in the untreated group.In contrast, a significant increase in NOx levels in the pioglitazone-treated group and ENG levels seems close to normal control, while a significant elevation of ICAM-1 and reduction in GSH levels.Although SGLT2 therapy caused a significant decrease in cholesterol and LDL, the level of ENG was significantly higher, and the level of GSH was considerably lower than in the other groups.In conclusion, the pioglitazone-treated group had the lowest HbA1c and blood pressure and was equivalent to the normal control group.The pioglitazone-treated group had the greatest amount of NOx, which prevents endothelial dysfunction, whereas the SGLT2 group had the lowest impact on these biomarkers.
No takes yet. Share an insight, caveat, or question.
Al-Hameed et al. (2024) conducted an observational in Type 2 Diabetes Mellitus (n=182). Antidiabetic medications (including pioglitazone and SGLT2 inhibitors) vs. Healthy controls and untreated patients was evaluated on Endothelial dysfunction biomarkers (NOx, ENG, ICAM-1, GSH). Pioglitazone treatment was associated with the lowest HbA1c and blood pressure and the highest NOx levels, whereas SGLT2 inhibitors had the lowest impact on these endothelial biomarkers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: